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Background/Objective: Maintenance of epidermal permeability barrier homeostasis is the most crucial
cutaneous function, as it allows life in a terrestrial environment. Defective epidermal permeability barrier
results not only in excessive water loss, but also in the induction of cutaneous inﬂammation and an
increased risk of infections. Together, these abnormalities could help explain the increased risk of death
in premature and low birth weight infants whose skin is functionally compromised. Improvement of
permeability barrier function by topical barrier repair therapies could become a valuable approach not
only to reduce neonatal mortality, but also to prevent/treat dermatoses, accompanied by barrier ab-
normalities at all ages, and to prevent microbial pathogen colonization/invasion. Yet, most current barrier
enhancing products are not optimal, and too expensive to allow their use in the developing countries.
Methods: we optimized the ratio of several inexpensive ingredients, previously shown to be effective
individually for barrier homeostasis. The effects of this mixture on epidermal functions barrier function,
skin surface pH and stratum corneum hydration, on murine skin were assessed using respective probe
connected to an MPA5 skin physiology monitor. Epidermal differentiation and antimicrobial peptide
expression were assessed by immnuohistochemical staining. Changes in lamellar body formation and
secretion were evaluated with an electron microscope.
Results: Although barrier function, skin surface pH and stratum corneum hydration remained unchanged
under basal conditions, our results show that pretreatment of normal murine skin with this optimized
mixture improves permeability barrier homeostasis, indicating by an acceleration of barrier recovery,
and enhances expression of antimicrobial peptides. The barrier-enhancing effects and antimicrobial
activities of this optimized mixture could be attributed at least in part to a parallel stimulation of
epidermal differentiation.
Conclusion: Since the individual ingredients in this mixture are inexpensive, this optimized mixture
shows promise as a means of reducing neonatal mortality in low-income settings, but it also could be
more widely used to prevent skin disorders associated with permeability and antimicrobial barrier
abnormalities.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.y have no ﬁnancial or non-
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Mortality rates for preterm (<37 weeks gestational age) and low
birth weight infants (<2500 g) are higher than for their term and
normal birth weight counterparts.1 This pertains particularly in low
income countries. For example, worldwide, more than 60% of pre-
term births occur in Africa and South Asia,2 and neonatal deaths
account for 50% of the infant mortality rate in Africa and other lowier Taiwan LLC. All rights reserved.
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declining recently, declines are slower than for older children and
efforts to decrease neonatal mortality rates remains a global pri-
ority.5 Improving the care of small neonates has been identiﬁed as
one of the interventions likely to have the greatest impact on
neonatal mortality.6
Applications of a range of emollients can reduce neonatal
mortality among preterm infants, decrease infection rates, and in-
creaseweight.7 However, themechanisms of action remain unclear.
In part, the beneﬁts of emollients in reducing neonatal mortality
can be attributed to the prevention of infection,8e10 but they also
could improve the epidermal permeability barrier. Indeed, recent
studies show how these two functions are integrated and coregu-
lated.11 This hypothesis is supported by a negative correlation be-
tween transepidermal water loss (TEWL), an indicator of epidermal
permeability barrier status, with both birth weight12 and gesta-
tional age,13e15 and the higher neonatal mortality rates found in
male compared to female neonates,16 the latter exhibiting superior
barrier function.17 Additionally, it is known that a compromised
permeability barrier simultaneously increases the risk of in-
fections,18 and increases the loss of body ﬂuid and body weight.19,20
Defective permeability barrier also increases energy consumption
in preterm infants, due to the high rates of calorie loss associated
with elevated rates of evaporative water loss.19 Given the ﬁndings
that topical emollients reduce systemic infections and neonatal
mortality in preterm infants,5,9,21 and the likelihood that this is due
to enhanced epidermal permeability barrier products to improve
epidermal permeability represent an effective strategy to reduce
neonatal mortality rates, particularly in preterm and low birth
weight infants, living in low-income countries.
Some products are already available to improve epidermal
permeability, including sunﬂower oil and Aquaphor (Beiersdorf Inc,
Wilton, Connecticut-06897, USA).8,14 Topical applications of these
barrier enhancing products have been shown to reduce mortality
rates by 26e32% in preterm infants.22 Although sunﬂower seed oil
is effective, its lipid composition, a key determinant of its efﬁcacy,
varies with the source of the oil. Moreover, the high proportion of
fatty acids in this and other oils can disturb the normal molar ratio
of lipids in the stratum corneum, potentially disrupting the
permeability barrier with a further risk of skin irritation.23 While
Aquaphor and petrolatum can instantly lower TEWL due to their
occlusive properties, occlusion inhibits endogenous restoration of
the natural permeability and antimicrobial barriers.11,24 Other
physiologic lipid-based products, such as EpiCeram (PuraCap
Pharmaceuticals, NJ, USA), improve permeability barrier function,
but their costly ingredients render them unaffordable in many
developing countries. In the present study, we optimized ratios of
several inexpensive ingredients, each of which was shown previ-
ously to improve barrier function individually,25,26 and evaluated
the effects of this optimized mixture on the permeability barrier
homeostasis in normal murine skin in comparison to EpiCeram, as
well as the mechanistic basis for its beneﬁts.
Materials and methods
Materials
Female albino hairless (SKH1) mice, 6e8 weeks old, were pur-
chased from Charles River Laboratories (Wilmington, MA, USA).
Ethanol and propylene glycol were purchased from Fisher Scientiﬁc
(Fairlane, NJ, USA). The optimized mixture, containing sunﬂower
oil, glycerol, borage oil, petrolatum, and lanolin, was prepared in-
house and vortexed prior to topical application. EpiCeram, a prod-
uct known to improve barrier function in atopic dermatitis,27e29
was used as a positive control. Afﬁnity-puriﬁed rabbit anti-mouseantibodies to ﬁlaggrin, involucrin, and loricrin were purchased
from BabCo (Richmond, CA, USA). Anti-mouse cathelin-related
antimicrobial peptide (CAMP) antibody was purchased from Santa
Cruz Biotechnology (Texas, USA). Secondary biotinylated goat anti-
rabbit IgG and an ABC-peroxidase kit were purchased from Vector
Laboratories (Burlingame, CA, USA). The antiproliferating cell nu-
clear antigen (PCNA, Ki-67) was purchased from CalTag Labora-
tories (Burlingame, CA, USA).
Experimental protocols and functional studies
All animal procedures were approved by the Animal Studies Sub-
committee (IACUC) of the San Francisco Veterans Administration
Medical Center and performed in accordance with their guidelines.
Mice were maintained in a temperature- and humidity-controlled
room, and given standard laboratory food and tap water ad libi-
tum. To determine whether repeated topical applications of the
optimized mixture improve epidermal function in normal mouse
skin, mice were topically treated with the optimized mixture twice
daily for 3 days. Untreated mice served as normal controls, and
mice treated with EpiCeram served as positive controls. Basal
epidermal biophysical properties were assessed by measuring
TEWL and stratum corneum hydration using respective probes
(TM300 for TEWL, and CM825 for hydration) connected to MPA5
(C&K, Cologne, Germany). A pH900 (C&K, Cologne, Germany) was
used to measure skin surface pH. For barrier recovery, TEWL was
measured at 0 hours and 2 hours after tape stripping, which
resulted in a 10-fold increase in TEWL, and percent barrier recovery
rates were calculated as described previously.30 To determine
whether single application of the optimized mixture improved
epidermal function in barrier-damaged mouse skin, mice were
tape-stripped, followed by immediate topical application of either
the optimized mixture or EpiCeram. Tape-stripped mice left
exposed to air served as controls. TEWL was measured at 0 hours, 1
hour, and 5 hours after tape stripping. The results were normalized
by untreated controls, setting the untreated controls as 100%.
Immunohistochemistry
The methods for assessment of both the differentiation markers
and proliferation were carried out as published previously.31,32
Brieﬂy, after deparafﬁnization and blocking with 4% bovine serum
albumin, 5 mm parafﬁn sections were incubated with primary
rabbit anti-mouse antibodies (Covance/BabCo., Berkeley, CA, USA)
at the dilutions of 1:2000 for ﬁlaggrin, 1:1000 for involucrin, and
1:500 for loricrin, overnight at 4C. After washing with 10 mM
citrate buffer, sections were incubated with goat anti-rabbit anti-
body (1:400) for 30 minutes at room temperature, followed by
ABC-peroxidase (Vector, Burlingame, CA, USA) reaction. For PCNA
staining, sections were incubated with biotinylated monoclonal
anti-PCNA antibody (CalTag Laboratories, Burlingame, CA, USA) for
2 hours at room temperature. The sections were visualized with a
Zeiss (Axioplan 2) microscope (Jena, Germany). Digital images were
captured with AxioVision software 2.05 (Carl Zeiss Vision, Munich,
Germany).
Electron microscopy
Skin biopsies from vehicle- and antagonist-treated mice (as above)
were ﬁxed in Karnovsky's ﬁxative overnight, and postﬁxed with
either 0.25% ruthenium tetroxide or 1% aqueous osmium tetroxide,
containing 1.5% potassium ferrocyanide, as described previously.32,33
Ultrathin sections were examined using an electron microscope
(Zeiss 10A, Carl Zeiss, Thornwood, NY, USA) operated at 60 kV.
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Data are expressed as the mean ± standard error of the mean
(SEM). The unpaired two-tailed Student t test with Welch's
correction was used to determine any signiﬁcant differences when
the two groups were compared.
Results
Optimized mixture accelerates permeability barrier recovery
After 3 days of the treatment with the optimized mixture, the
overall gross appearance of the skin was similar between treated
and untreated mice. Inﬂammation was not evident histologically,
nor was epidermal proliferation abnormal, as assessed by hema-
toxylin and eosin (H&E) and PCNA staining, respectively (data not
shown). We then assessed the impact of this optimized mixture on
the epidermal biophysical properties in normal skin. As shown in
Figure 1A, pretreatment with the optimized mixture did not alter
the biophysical properties of normal murine skin under basal
conditions. In contrast, permeability barrier recovery signiﬁcantly
accelerated in treated skin 2 hours after barrier disruption, in
comparison with untreated controls, and more rapidly than in the
sites treated with EpiCeram, a known barrier enhancer (Figure 1A).
Since epidermal permeability barrier is compromised in both
preterm and low birth weight infants, we next determinedwhether
this optimized mixture improves epidermal permeability barrier in
skin with a perturbed barrier. Our results show that a single topical
application of either the optimized mixture or EpiCeram signiﬁ-
cantly reduced TEWL 1 hour after barrier disruption (Figure 1B), but
no differences were seen between untreated controls and those
treated with either the optimized mixture or EpiCeram 5 hoursFigure 1 Topical optimized mixture improves epidermal permeability barrier homeostasis
inﬂuences of topical optimized mixture and EpiCeram on statum corneum biophysical prope
EpiCeram on permeability barrier homeostasis after a single application to barrier disrupte
lines. N and signiﬁcances are indicated in the ﬁgures. TEWL ¼ transepidermal water loss.after application. These results demonstrate that topical applica-
tions of the optimized mixture improve epidermal permeability
homeostasis in both normal and perturbed skin.
Topical optimized mixture stimulates epidermal differentiation
Because epidermal differentiation-related proteins are key de-
terminants for epidermal permeability barrier,34we next determined
whether the topical optimizedmixture upregulates the expression of
epidermal differentiation-related proteins, which provide a mecha-
nism whereby the mixture improves permeability barrier homeo-
stasis. Indeed, the intensity of immunostaining for involucrin was
markedly enhanced following 3 days of treatment with either the
topical optimized mixture or EpiCeram (Figure 2E, F vs. D), while the
intensity of epidermal ﬁlaggrin (Figure 2A vs. B and C) staining
remained unchanged. The optimized mixture did not alter the
expression of loricrin, while a slight reduction in loricrin expression
was evident following EpiCeram applications. These results suggest
that topical optimizedmixture could improve barrier function inpart
by enhancement of epidermal involucrin expression.
Topical optimized mixture stimulates lamellar body formation
Since formation of both the permeability and antimicrobial barriers
requires secretion of lamellar body content,35 we next assessed the
changes in lamellar body formation following 3 days of topical
treatments with optimized mixture. As seen in Figure 3B, more
lamellar bodies are present in the cytosol of the stratum gran-
ulosum following topical treatment with the optimized mixture in
comparisonwith untreated skin (Figure 3A). Moreover, acceleration
of membrane bilayer maturation became evident in optimized
mixture-treated skin (arrows in Figure 3D) in comparison with. Mice were treated as described in the materials and method section. (A) depicts the
rties after 3 days of treatment; (B) displays the effects of topical optimized mixture and
d murine skin. Results were normalized by untreated controls as shown by the dotted
Figure 2 Topical optimized mixture stimulates epidermal differentiation. After 3 days of treatments with either topical optimized mixture or EpiCeram, skin samples were taken for
immunohistochemical staining of differentiation marker proteins. (A), (D), (G) are untreated normal controls; (B), (E), (H) are EpiCeram-treated skin; (C), (F), (I) are optimized
mixture-treated skin. Magniﬁcation bar ¼ 50 mm.
Figure 3 Topical optimized mixture stimulates lamellar body formation. After 3 days of treatments, skin biopsies were taken for ultrastructural analysis. (A) represents lamellar
bodies, as indicated by arrows, in an untreated sample; (B) represents lamellar bodies, as indicated by arrows, in an optimized mixture-treated sample; (C) displays lipid processing
(see arrow) in an untreated sample; (D) displays lipid processing (see arrow) in an optimized mixture-treated. Magniﬁcations for A and B are the same and magniﬁcation
bar ¼ 1 mm. Magniﬁcations for C and D are the same and magniﬁcation bar ¼ 0.5 mm.
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Figure 4 Topical optimized mixture upregulates the expression of epidermal antimicrobial peptide. After 3 days of treatments with either topical optimized mixture or EpiCeram,
skin samples were taken for immunohistochemical staining of CAMP: (A) untreated control; (B) EpiCeram-treated sample; (C) optimized mixture-treated sample. All pictures were
taken at the same magniﬁcation. Magniﬁcation bar ¼ 40 mm. CAMP ¼ cathelicidin-related antimicrobial peptides.
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optimized mixture-induced enhancement of epidermal perme-
ability barrier homeostasis can be attributed, at least in part, to the
stimulation of lamellar body formation and accelerated membrane
bilayer maturation.
Topical optimized mixture upregulates the expression of
epidermal antimicrobial peptide
Previous studies have demonstrated that epidermal antimicrobial
peptides, such as CAMP, not only provide a barrier against infection,
but also are crucial for permeability barrier.11 Moreover, the
expression levels of CAMP are lower in preterm infants than in full-
term neonates.36 Thus, we next assessed whether treatment with
the optimized mixture enhances expression of epidermal CAMP,
providing an additional, potential mechanism for the improvement
of permeability barrier and antimicrobial defense, also providing a
further rational for its clinical usage in treating preterm infants. As
shown in Figure 4, a dramatic increase in the intensity of CAMP
immunostaining became evident following treatment with both
the optimized mixture and EpiCeram for 3 days in comparisonwith
untreated controls (Figure 4A vs. B and C). These results demon-
strate that the topical optimized mixture enhances the expression
of a key epidermal antimicrobial peptide, i.e., CAMP.Figure 5 The putative mechanisms by which topical optimized mixture improves permeab
permeability barrier while glycerol accelerates permeability barrier repair. Linoleic acids in
lipids and antimicrobial peptides, and stimulation of lamellar body secretion and membra
improved. PPAR ¼ peroxisome proliferator-activated receptors; SC ¼ stratum corneum.Discussion
Previous studies have shown that improving epidermal perme-
ability barrier through topical applications of emollients reduces
neonatal mortality rates in preterm infants.22,37 These agents can
increase body weight,7 prevent systemic infection,38 and delay the
development of atopic dermatitis.39 Although emollients such as
sunﬂower oil and Aquaphor show promise as a means of improving
barrier function,8 they still have certain limitations. For example,
fatty acid (a key determinant for permeability barrier) composition
of sunﬂower oil varies with sources, consequently affecting its
clinical efﬁcacy. Aquaphor can improve permeability barrier, but
with no beneﬁts for the reduction of infection risk,10 whereas both
defective permeability barrier and infection are separate risk fac-
tors for neonatal deaths. Therefore, there is a need to develop
products that speciﬁcally address the required permeability and
antimicrobial barriers in preterm neonates. In the present study, we
developed an optimized mixture that improves epidermal perme-
ability barrier in both intact and barrier-damaged skin. The un-
derlying mechanisms by which this optimized mixture improves
epidermal permeability barrier includes stimulation of epidermal
differentiation, upregulation of epidermal antimicrobial peptide
expression, and increased lamellar body formation. Epidermal
differentiation-related proteins are critical components of “bricks”ility barrier homeostasis. In the mixture, petrolatum and lanolin instantly improve the
both sunﬂower oil and borage oils activate PPAR, resulting in increased productions of
ne maturation. Consequently, both permeability barrier and antimicrobial barriers are
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postsecretory organization of extracellular lipids.34,40 Pertinently, a
deﬁciency in involucrin compromises epidermal permeability
barrier,41 and here, we show that topical applications of the opti-
mized mixture dramatically increases the expression of involucrin.
In addition, epidermal antimicrobial peptides provide not only an
antimicrobial barrier, but also contribute to the permeability bar-
rier.11 We showed previously that CAMP deﬁciency delays perme-
ability barrier recovery in mice.11 Thus, upregulation of epidermal
CAMP expression could be another potential mechanism for the
improved permeability barrier function in skin treated with the
optimized mixture.
Lamellar bodies are the epidermal organelles that deliver lipids
and CAMP to the stratum corneum interstices.11,42 Further matu-
ration and transformation of secreted lipid precursors into mem-
brane bilayers is required for the formation of a competent
permeability barrier. In the present study, increased numbers of
lamellar bodies and acceleration of membrane bilayer maturation
became evident in skin treated with the optimized mixture,
providing an additional mechanism by which the optimized
mixture could improve permeability and antimicrobial barrier
function in parallel. All these changes in epidermal function,
induced by the optimized mixture, are likely mediated by peroxi-
some proliferator-activated receptors (PPARs), because both the
borage oil and sunﬂower seed oil in the mixture contain linoleic
acid and g-linoleic acid, which are PPAR activators. Activation of
PPARg stimulates epidermal differentiation, and lamellar body
formation and secretion. In particular, PPARg is required for 1a,25-
dihydroxyvitamin D3-induced involucrin expression.43 Likewise,
PPARg also mediates 1a,25-dihydroxyvitamin D3-induced hBD-3
and cathelicidin expression in keratinocytes.44,45 Possible mecha-
nisms whereby this optimized mixture improves epidermal
permeability and antimicrobial barrier functions are illustrated in
Figure 5.
It is worth noting that the novelty of this mixture is that all of
the ingredients and their concentrations are chosen for optimal
efﬁcacy, thereby eliminating the need for additional ingredients
that could increase cost and potentially cause adverse effects. For
example, all ingredients in this mixture can increase stratum cor-
neum hydration, which is abnormally reduced in many skin dis-
orders, such as atopic dermatitis, psoriasis, ichthyosis, and aged
skin. The lower concentrations of petrolatum and lanolin in the
mixture instantly reduce TEWL, without producing excessively
occlusive effects, which could potentially delay endogenous re-
sponses to external insults, and delay permeability barrier repair.
These two ingredients are particularly useful for correcting barrier
function in barrier-damaged skin. Moreover, lower concentrations
of sunﬂower oil and borage oil in this mixture reduces greasiness
and potential irritant effects, without sacriﬁcing beneﬁts. Although
there are still no clinical data for the utility of this optimized
mixture in preterm humans, the following beneﬁcial effects of the
optimized mixture on epidermal function nonetheless provide a
strong rationale for its clinical applications.
1. Accelerating barrier repair without altering basal barrier function:
An optimal permeability barrier is required for epidermal ho-
meostasis. Protection with occlusive products can reduce TEWL,
but also inhibit cellular metabolism. Of course, a compromised
barrier causes skin diseases. This optimized mixture maintains
barrier function at its normal level while accelerating barrier
repair upon requirement (barrier disruption). Therefore, this
mixture could serve as a skin emergency kit and could be
routinely applied to normal skin. The barrier could be quickly
repaired once the barrier gets damaged such as in aged skin
where barrier recovery is delayed.2. Improving barrier in barrier damaged skin: Barrier disruption not
only stimulates epidermal proliferation and induces inﬂamma-
tion, but also facilitates bacterial invasion and allergen pene-
tration. Thus, this mixture could be very useful for the
prevention of inﬂammation and infection in barrier-damaged
skin such as infants, particularly premature infants who are
predisposed to skin infections.
3. Enhancing antimicrobial defense through increased antimicrobial
peptide production: In addition to the impact on permeability
barrier function, epidermal antimicrobial peptides play a key
role against microbial infection. Infants, especially premature
infants, are more vulnerable to bacterial infections, largely due
to premature innate immunity. Also, infection is among the
major causes of infant mortality. Moreover, both atopic derma-
titis and ichthyosis are at higher risk for certain types of infec-
tion. Since this optimized mixture can upregulate epidermal
antimicrobial peptide expression and improve barrier function,
it could be useful for infants and other dermatoses.Conclusion
Because this inexpensive formulation improves epidermal perme-
ability barrier function and antimicrobial defense, it could be useful
for the treatment of neonatal and aged skin, as well as inﬂamma-
tory dermatoses characterized by barrier abnormalities.
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